Theralase Technologies Inc. · TSXV:TLT
Theralase Technologies — Investor Presentation (June 2025)
39 slides from Theralase Technologies's investor presentation, Jun 11, 2025
Slide 1: Destroying Cancer at the Speed of Light
Destroying Cancer at the Speed of Light® Healing at the Speed of Light® June 11, 2025 TSXV:TLT | OTCQB:TLTFF
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 Forward-Looking Statements (“FLS”) contained in this presentation deal with the future revenue potential, business opportunities and/or strategic initiatives of Theralase® Technologies Inc. (“Theralase®” or the “Company”); including, information, analyses and/or projecti
Slide 3: Research
Research 3 Cutting Edge Scientific Pipeline Clinical Studies Management Team Intellectual Property and Preclinical Primary Indication Phase II NMIBC registration clinical Extensive experience in:1 29 issued patents and 17 Research study interim clinical data nearing Drug Discovery patents pending fo
Slide 4: Intellectual Property
Intellectual Property1 4 Expiry Patent Description April 2033 Metal-Based Thiophene Photodynamic Compounds and Their Use Protects Ruvidar® and all associated molecules in the USA, Canada, Russia, China, Europe, Brazil and India March 2034 Metal-Based Coordination Complexes as Photodynamic Compounds
Slide 5: Ruvidar® (TLD-1433)
Ruvidar® (TLD-1433) 5 • Ruthenium-based small molecule • Designed to destroy solid core tumours (i.e.: bladder, brain, lung and breast) when absorbed by the cancer cell • Highly effective in the destruction of viruses (i.e.: Influenza, Zika, coronaviruses, HSV) • Activity is significantly enhanced w
Slide 6: Theralase Device Division Pipeline
Theralase® Device Division Pipeline 6 Prototype Phase III Health Canada Product Indication Concept Safety Testing Commercial Stage Clinical Study / FDA Approved TLC-2000 Cool Laser Therapy Pain Management (Professional Use) Non-Muscle TLC-3200 Medical Laser System Invasive Bladder (Professional Use)
Slide 7: Theralase Drug Division Pipeline
Theralase® Drug Division Pipeline 7 Indication Candidate Pre- GLP Phase 0 Phase I Phase II Phase III FDA Clinical Toxicology Approved Non-Muscle Invasive Bladder Cancer RuvidarTM + Not (“NMIBC”) TLC-3200 Required Herpes Simplex Virus (“HSV”)-1 RuvidarTM Glio Blastoma Multiforme (“GBM”) Rutherrin® +
Slide 8: What is Cancer?
What is Cancer? 8 • Cancer = Cells that sustain DNA damage and become immortal • Normal cells grow - then die • Cancer cells ignore these signals and continue to multiply, leading to tumours and eventually death, if not destroyed • Each human has approximately 30 trillion cells in our bodies (200 di
Slide 9: Mechanism of Action (Cancer)
Mechanism of Action (Cancer) Visible or Near Infra Red Light, 9 Transferrin Radiation, Sound and/or Drug-Activated Receptor (“TfR”)2 Rutherrin + TfR 1O 2 RuvidarTM ROS Cancer cell destruction via Rutherrin®1 Cancer Cell Immunogenic Cell Death (“ICD”)3 Ruvidar® Retained Ruvidar® Healthy Cell Not Take
Slide 10: Non-Muscle Invasive Bladder Cancer
10 Non-Muscle Invasive Bladder Cancer
Slide 11: Bladder Cancer
Bladder Cancer 11 Non-Muscle Invasive Bladder Cancer (“NMIBC”) 9th Most Common Cancer Worldwide 4th leading cancer in men1 Muscle Invasive Bladder 84,870 in US1 Cancer (“MIBC”) 12,300 in Canada2 200,000 in Europe3 614,298 in World4 1) Key Statistics for Bladder Cancer | American Cancer Society (2025
Slide 12: Study Treatment
Study Treatment 12 Bladder cancer cells Ruvidar® instilled Ruvidar® localizes Green laser light destroyed by the in bladder via catheter preferentially inside activates Ruvidar® production of singlet demonstrating bladder cancer cells 2,3 through fiber optics oxygen and / or Reactive absorption into
Slide 13: Phase II NMIBC Interim Clinical Data
Phase II NMIBC Interim Clinical Data1 13 PREVIOUS BCG THERAPY AGE RACE TREATMENTS SEX STAGE <7 Non-White CIS + Ta ≤ 65 Female 5% 20% 19% 17% CIS + T1 6% 14% > 65 Male White CIS ≥7 80% 81% 83% 80% 95% Ruvidar® has been demonstrated to achieve complete responses in patients, previously treated with an
Slide 14: Study Procedure
Study Procedure 14 • 90 patients with BCG-Unresponsive NMIBC CIS (82 patients treated to date, 8 patients to be completed by July 2025) • 12 clinical study sites currently enrolling patients in Canada and the United States • Patient provided primary Study Procedure on Day 0 (1 hour of drug instillat
Slide 15: Phase II NMIBC Interim Clinical Data
Phase II NMIBC Interim Clinical Data1 15 Primary Endpoint Performance (CR at any Point in Time) # % Confidence Interval (95%) Primary Endpoint Complete Response 43/69 62.3% [43.7, 80.9] ("CR") Total Response (CR 48/69 69.6% [49.9, 89.2] and IR) Secondary Endpoint Performance (Duration of CR) (450 Da
Slide 16: NMIBC FDA Approved Drugs
NMIBC FDA Approved Drugs 16 Initial Company/ FDA Complete Duration of Market Approved Drug Number of Response Response Annual Cost Capitalization (Date of Approval) Patients (“CR”) (12 months) (24 months) (36 months) Pros Cons ($USD 000s) ($USD Billion) IBCG Guidelines 92 60.0% 30.0% 20.0% 15.0% (ex
Slide 17: NMIBC Non-FDA Approved Drugs
NMIBC Non-FDA Approved Drugs 17 Initial Number Complete Duration of Market Competitive Drug of Response Response Annual Cost Capitalization (Non-FDA Approved) Patients (“CR”) (12 months) (24 months) (36 months) Pros Cons ($USD 000s) ($USD Billion) IBCG Guidelines 92 60.0% 30.0% 20.0% 15.0% (extrapol
Slide 18: Herpes Simplex Virus
Herpes Simplex Virus thera SE
Slide 19: What is HSV?
What is HSV? 19 There are hundreds of known types of herpes viruses, but only 8 routinely infect humans1 There are two main types of Herpes Simplex Virus (“HSV”) that are most prevalent in humans:2 Type Symptoms Global Prevalence (Billions) % of Population (Under age 50) HSV-1 Cold Sores 3.8 64% HSV
Slide 20: Mechanism of Action
Mechanism of Action Ruvidar® 20 Glycoproteins (gB and gC) on HSV are negatively charged.1,2 +- +- -+ + +- - -+ They interact with Heparan Sulfate (“HS”) on the cell surface, +- which is also negatively charged.3,4 - -+ + -+ This provides a novel mechanism (based on controlled + -- - + +- -+ + electr
Slide 21: Herpes Simplex Virus
Herpes Simplex Virus1 21 3.8 billion people (64%) worldwide (Age < 50) have HSV-1 0.5 billion people (13%) worldwide (Age 15 to 49) have HSV-2 Global market size estimated at $USD 2.8 billion in 2024 and is expected to grow to $USD 4.7 billion by 2033.2 North America has the largest market share at
Slide 22: Preclinical Research
Preclinical Research1 22 Effects of Ruvidar® Versus Acyclovir on HSV-1 Yields When Added 24 Hours Post Infection (“HPI”). 1) Theralase® Releases Latest Research on Inactivation of Herpes Simplex Viruses. February 10, 2025
Slide 23: Preclinical Research
Preclinical Research1 23 Prior to RuvidarTM Treatment After 4 days of RuvidarTM Treatment Four days of daily Ruvidar® treatment in Balb/C mice with HSV-1 infected cutaneous lesions, 4 days post infection 1) Theralase® Demonstrates Effective Treatment of Herpes. February 13, 2025
Slide 24: Preclinical Research
Preclinical Research1 24 No Treatment Acyclovir (5%) Abreva (10%) RuvidarTM (1%) (5 days of treatment / 5 times per day) (6 days of treatment / 5 times per day) (5 days of treatment / once per day) Balb/C mice with HSV-1 infected cutaneous lesions, 1 day post-infection 1) Ruvidar More Effective in t
Slide 25: HSV FDA Approved Drugs
Bladder HSV FDA Cancer Drugs Approved 25 Mode of Administration / Drug Cost ($USD) Per Drug1,2 Pros Cons Frequency Treatment3 / Manufacturer Prescription Use Only. Acyclovir resistance can occur $62 (generic) to $95 (Bausch / in immunocompromised Zovirax Topical Standard of care for labial and Glaxo
Slide 26: HSV Non-FDA Approved Drugs
Bladder Cancer HSV Non-FDA Approved Drugs 26 Mode of Administration / Drug Cost ($USD) Per Treatment / Drug1 Pros Cons Frequency Manufacturer Over the Counter Not FDA approved. He-X Topical TBD (Theralase®) High safety and efficacy Phase I/II/III clinical study to be (1% RuvidarTM) (1 time per day f
Slide 27: New Cancer Indications
New Cancer Indications mera SE
Slide 28: GBM Preclinical Research
GBM Preclinical Research 28 Destruction of Human Glioma Cells Treated with Radiation-Activated Rutherrin® Versus Radiation Alone
Slide 29: NSCLC Preclinical Research
NSCLC Preclinical Research 29 Tumour Volume Analysis in Mice After Tumour Inoculation and Treatment with Either Radiation Alone or a Combined Treatment of Rutherrin ® and Radiation Treatment
Slide 30: MIBC Preclinical Research
MIBC Preclinical Research 30 Tumour Destruction Intact Muscle Full Depth Tumour Necrosis in Muscle Invasive Bladder Tumours (No Damage to Healthy Muscle Tissue (Light-activated Ruvidar®))
Slide 31: Leukemia, Lymphoma and Myeloma Preclinical Research
Leukemia, Lymphoma and Myeloma Preclinical Research 31 Evaluation of Lymphoma in a Mouse Model
Slide 32: Regulatory Timeline (NMIBC)
Regulatory Timeline (NMIBC) 32 Milestone 2019 2020 2021 2022 2023 2024 2025 2026 2027 90 Patients Enrolled and Provided Primary Study Treatment (Projected) FDA Fast Track Designation (Actual) Patient Follow Up (Projected) Premarket Approval (Study Device) (Projected) Data Lock / Clinical Study Repor
Slide 33: Regulatory Timeline (HSV-1)
Regulatory Timeline (HSV-1) 33 Milestone 2025 2026 2027 2028 Formulation of HSV topical cream (Projected) GLP Toxicology (Projected) Phase I /II Clinical Study (Projected) Phase III Clinical Study (Projected) Data Lock / Clinical Study Report Submission (Projected) Health Canada and FDA Marketing Ap
Slide 34: Regulatory Timeline (GBM, NSCLC, Pancreatic, Colorectal)
Regulatory Timeline (GBM, NSCLC, Pancreatic, Colorectal) 34 Milestone 2025 2026 2027 2028 2029 2030 Formulation of IV Rutherrin®(Completed) GLP Toxicology (Projected) Phase I /II Clinical Study (Projected) Phase III Clinical Study (Projected) Data Lock / Clinical Study Report Submission (Projected)
Slide 35: NMIBC Investment Highlights
NMIBC Investment Highlights 35 • Next standard of care treatment for bladder cancer (9th most common cancer in the world (4th in men)) • Unique value proposition, combining a patented small molecule and proprietary laser system • Able to directly destroy bladder cancer, leaving healthy bladder cells
Slide 36: HSV Investment Highlights
HSV Investment Highlights 36 • Next standard of care treatment for HSV-1 lesions (cold sores) • Ability to treat with a patented small molecule alone or increase efficacy with a proprietary laser system • High safety and efficacy in preclinical models • Pending Health Canada, FDA and international a
Slide 37: Other Cancer Indications Investment Highlights
Other Cancer Indications Investment Highlights 37 • Minimally invasive treatment that provides IV installation of Rutherrin® activated by radiation therapy • Patient centric treatment • High safety and efficacy in preclinical models • Pending Health Canada, FDA and international approval in 2030, Th
Slide 38: Capital Structure
Capital Structure 38 TSXV:TLT 06/04/2025 Common share price $CAN 0.185 Warrants 45,314,721 Market Capital $CAN 46.4 M Options 19,620,000 Shares Outstanding 250,810,200 Finder Units 18,864 Insider Fully Diluted 315,763,785 12.75% Fully Diluted Ownership
Slide 39: Contact Information
Contact Information Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir. President and Chief Executive Officer rwhite@theralase.com, 416.699.5273 x 225 Arkady Mandel, M.D., Ph.D., D.Sc. Chief Scientific Officer Toll Free: 1.866.THE.LASE (843.5273) amandel@theralase.com, 416.699.5273 x 260 Work: 416.699.LAS
Theralase Technologies — Investor Presentation (June 2025) on 6ix